

PRODUCT INFORMATION

Seglitide (acetate)

Item No. 42497

Formal Name: cyclo(N-methyl-L-alanyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-phenylalanyl), acetate

Synonyms: Cyclic [N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe], MK-678

Peptide Sequence: cyclo(XYwKVF) (X=N-methylalanine)

MF: $C_{44}H_{56}N_8O_7 \cdot XC_2H_4O_2$


FW: 809.0

Purity: $\geq 98\%$

Supplied as: A solid

Storage: -20°C

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Seglitide (acetate) is supplied as a solid. A stock solution may be made by dissolving the seglitide (acetate) in the solvent of choice, which should be purged with an inert gas. Seglitide (acetate) is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of seglitide (acetate) can be prepared by directly dissolving the solid in aqueous buffers. Seglitide (acetate) is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Seglitide is an agonist of somatostatin receptor 2 (SST₂).¹ It inhibits forskolin-induced cAMP accumulation in CCL-39 cells expressing recombinant human SST₂ (EC₅₀ = 0.093 nM) but also those expressing recombinant human SST₃ or SST₅ (EC₅₀s = 209 and 0.47 nM, respectively), of which all are subtypes of the group 1 SST receptor, also known as the somatotropin release inhibiting factor 1 (SRIF₁) receptor. However, at higher concentrations, seglitide inhibits somatostatin-14-, somatostatin-25-, or somatostatin-28-induced developed tension in spontaneously beating guinea pig right atria (pA₂s = 6.5, 6.24, and 6.09, respectively).² Seglitide selectively binds to SST₂, SST₃, and SST₅ (K_ds = 0.15, 21, and 0.06 nM, respectively, using CGP 23996 as the radioligand) over SST₁ and SST₄, which comprise the SRIF₂ receptor (K_ds = 13.5 and 9.1 μM , respectively, using CGP 23996 as the radioligand).³ It inhibits gastrin-, dimaprit-, or IBMX-induced acid secretion in isolated rat gastric mucosa (EC₅₀s = 6, 17, and 13 nM, respectively).⁴ *In vivo*, seglitide (500 ng/animal) increases extracellular dopamine levels in the ipsilateral nucleus accumbens in rats when infused into the ventral subiculum.⁵

References

1. Siehler, S. and Hoyer, D. *Naunyn Schmiedeberg's Arch. Pharmacol.* **360**(5), 510-521 (1999).
2. Dimech, J., Feniuk, W., and Humphrey, P.P. *Br. J. Pharmacol.* **109**(4), 898-899 (1993).
3. Siehler, S., Seuwen, K., and Hoyer, D. *Naunyn Schmiedeberg's Arch. Pharmacol.* **360**(5), 488-499 (1999).
4. Wyatt, M.A., Jarvie, E., Feniuk, W., et al. *Br. J. Pharmacol.* **119**(5), 905-910 (1996).
5. Mitchell, S.N., Sharrott, A., Cooper, J., et al. *Eur. J. Pharmacol.* **395**(1), 43-46 (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/21/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM